In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Generics
The existing interruptions in the supply of active pharmaceutical ingredients (APIs) to Russia and lack of their production within the country currently remains one of the major reasons for a shortage of various drugs in the local market, reports The Pharma Letter’s local correspondent. 31 January 2023
Biotechnology
An analysis of the recent progress in RNA therapeutics and future opportunities. 31 January 2023
Biotechnology
A rosy future is predicted for Sino-American biotech BeiGene oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib), which recently gained US Food and Drug Administration (FDA) approval for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). 31 January 2023
Pharmaceutical
Today (January 31) marks the start of the mandatory application of the Clinical Trials Regulation for all new clinical trials. It is a significant milestone in the transformation of the oversight and management of clinical trials in the European Union. 31 January 2023
Pharmaceutical
The Belgian pharmaceutical industry has raised concerns around pressures being applied to the national healthcare budget for innovative medicines. 30 January 2023
Biotechnology
Oxford University spin-out Vaccitech (Nasdaq: VACC today announced the appointment of Nadège Pelletier as chief scientific officer (CSO), to replace Tom Evans, who is retiring but will remain involved as a scientific consultant to the company. 30 January 2023
Pharmaceutical
Analysis from financial services company PwC shows optimism for the year ahead in pharmaceutical M&A in the UK market. 30 January 2023
Pharmaceutical
Pharmaceutical production in Russia in 2022 grew by more than 15% compared to 2021, while the industry continues to increase its technological independence, according to recent statements, by Russia’s Deputy Prime Minister Denis Manturov – a state official personally responsible for the development of pharmaceutical sector in the Russian government, reports The Pharma Letter’s local correspondent. 30 January 2023
Biotechnology
The market for acute lymphocytic leukemia (ALL), the most commonly diagnosed form of leukemia, is expected to see strong growth at a compound annual growth rate (CAGR) of 5% over the next decade across the world’s eight major markets (8MM). 30 January 2023
Pharmaceutical
US Senator Elizabeth Warren (Democrat, Massachusetts) has urged the Federal Trade Commission to look closely at two pending pharmaceutical mergers, insisting that the deals could lead to higher drug prices and prevent "affordable alternatives from entering the market." 30 January 2023
Biotechnology
Preliminary results from the ongoing global Phase III STAND study in sickle cell disease are not what Novartis had hoped. 30 January 2023
Biotechnology
Positive results from the Phase III CARTITUDE-4 study show the novel BCMA-directed T-cell therapy Carvykti (ciltacabtagene autoleucel) performed well in the treatment of multiple myeloma. 30 January 2023
Generics
The US industry has said that India should come out with a research and development (R&D) policy for its pharmaceutical sector. 30 January 2023
Pharmaceutical
The world’s leading biopharma companies experienced growth in market capitalization of 5.4% on average last year, according to industry analyst GlobalData. 30 January 2023
Biotechnology
Adding yet another indication for Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) blockbuster interleukin (IL)-13 and IL-4 blocking antibody Dupixent (dupilumab), the European Commission (EC) has expanded the marketing authorization to treat eosinophilic esophagitis (EoE). 30 January 2023
Pharmaceutical
Privately-held Italian drugmaker Chiesi Farmaceutici today announced the appointment of Giuseppe Accogli as company’ new chief executive (CEO). 30 January 2023
Pharmaceutical
Israel-based dermatology focussed biotech Sol-Gel Technologies says it has acquired rights to the topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from US drug developer PellePharm. 30 January 2023
Biotechnology
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at University of Texas MD Anderson Cancer Center. 30 January 2023
Biotechnology
Last Monday Japanese pharma giant Takeda announced a licensing deal with China’s Hutchmed for rights to the latter’s colorectal cancer drug Elunate (fruquintinib). On the research front, US pharma giant Merck & Co released new clinical data for its mega-blockbuster cancer drug Keytruda in two therapy settings – one positive and one missing its endpoint. Also, Ocuphire released top-line Phase II data on its diabetic retinopathy candidate APX3330 that failed to meet the primary endpoint of the study. There was also positive news for Merck &Co, with the US Food and Drug Administration granting a new indication for Keytruda as adjuvant treatment in lung cancer. 29 January 2023
Pharmaceutical
The US Food and Drug Administration (FDA) has granted accelerated approval to Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma (MCL) - a rare blood disorder - after at least two lines of systemic therapy, including a BTK inhibitor. 28 January 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze